What German Family Doctors Think About Cannabis Legalization

Most German primary care physicians expected cannabis use and disorders to increase after legalization, yet few screened patients for cannabis use or wanted additional training.

Hochheim, Uta et al.·Journal of cannabis research·2025·lowcross-sectional survey
RTHC-06671Cross Sectional surveylow2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cross-sectional survey
Evidence
low
Sample
Not reported

What This Study Found

Among 239 responding physicians, most anticipated increased cannabis consumption and disorders post-legalization. Doctors with personal cannabis experience (37.9%) were more optimistic about policy goals like quality control. Despite 40.3% prescribing medical cannabis, screening for recreational use was rare.

Key Numbers

25.3% response rate (239 of 946). 37.9% of respondents had personal cannabis experience. 40.3% prescribed medical cannabis. Most anticipated increased consumption and cannabis use disorders after legalization.

How They Did This

Exploratory cross-sectional survey of GPs and practice-based anesthesiologists in three German states, conducted from September 2023 to March 2024 (pre-legalization). 946 surveys delivered, 239 responded (25.3% response rate).

Why This Research Matters

Primary care physicians are often the first point of contact for patients experiencing cannabis-related health issues, making their preparedness and attitudes relevant to post-legalization healthcare.

The Bigger Picture

The gap between prescribing medical cannabis (40.3%) and actively screening for recreational use reflects a broader pattern seen internationally, where healthcare systems have been slow to integrate cannabis screening into routine care even as legalization expands.

What This Study Doesn't Tell Us

Low response rate (25.3%) introduces selection bias. Only three of sixteen German states surveyed. Pre-legalization timing means attitudes may shift with actual experience. Self-selected respondents may differ systematically from non-respondents.

Questions This Raises

  • ?Will physician attitudes shift after experiencing the post-legalization reality?
  • ?Would structured cannabis screening tools increase detection of problematic use in primary care?

Trust & Context

Key Stat:
40.3% of physicians prescribed medical cannabis, but few routinely screened for recreational use
Evidence Grade:
Low response rate (25.3%) in a limited geographic area, pre-legalization timing, and exploratory design limit generalizability.
Study Age:
2025 publication with data collected September 2023 to March 2024, before Germany legalized recreational cannabis.
Original Title:
Attitudes and expectations of primary care physicians regarding recreational cannabis legalization in Germany: a pre-implementation survey.
Published In:
Journal of cannabis research, 7(1), 101 (2025)
Database ID:
RTHC-06671

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-06671·https://rethinkthc.com/research/RTHC-06671

APA

Hochheim, Uta; Müller, Frank; Noack, Eva Maria. (2025). Attitudes and expectations of primary care physicians regarding recreational cannabis legalization in Germany: a pre-implementation survey.. Journal of cannabis research, 7(1), 101. https://doi.org/10.1186/s42238-025-00367-8

MLA

Hochheim, Uta, et al. "Attitudes and expectations of primary care physicians regarding recreational cannabis legalization in Germany: a pre-implementation survey.." Journal of cannabis research, 2025. https://doi.org/10.1186/s42238-025-00367-8

RethinkTHC

RethinkTHC Research Database. "Attitudes and expectations of primary care physicians regard..." RTHC-06671. Retrieved from https://rethinkthc.com/research/hochheim-2025-attitudes-and-expectations-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.